The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Syneron Medical's revenues will shrink -2.4% and EPS will turn positive
The average estimate for revenue is $61.2 million. On the bottom line, the average EPS estimate is $0.02.
Last quarter, Syneron Medical booked revenue of $72.8 million. GAAP reported sales were 19% higher than the prior-year quarter's $61.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.11. GAAP EPS were $0.14 for Q4 compared to -$0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 49.5%, 30 basis points better than the prior-year quarter. Operating margin was 0.7%, much worse than the prior-year quarter. Net margin was 7.1%, much better than the prior-year quarter.
The full year's average estimate for revenue is $289.9 million. The average EPS estimate is $0.47.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 700 members out of 732 rating the stock outperform, and 32 members rating it underperform. Among 178 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 172 give Syneron Medical a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.38.
Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Syneron Medical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.